Evidence map›Paper›PMID 38681092›Full record

ReviewInternational journal of nanomedicine2024

Bladder Cancer in Exosomal Perspective: Unraveling New Regulatory Mechanisms.

Cong Yin, Cen Liufu, Tao Zhu, Shuai Ye, Jiahao Jiang, Mingxia Wang, Yan Wang, Bentao Shi

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cong Yin *Department of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, People's Republic of China.
Cen Liufu *Department of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen PKU-HKUST Medical Center, Shenzhen, People's Republic of China.ORCID 0009-0009-4479-8695
Tao ZhuDepartment of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen PKU-HKUST Medical Center, Shenzhen, People's Republic of China.
Shuai YeDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, People's Republic of China.
Jiahao JiangDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, People's Republic of China.
Mingxia WangDepartment of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen PKU-HKUST Medical Center, Shenzhen, People's Republic of China.
Yan WangDepartment of Urology, Peking University Shenzhen Hospital, Institute of Urology, Shenzhen PKU-HKUST Medical Center, Shenzhen, People's Republic of China.ORCID 0000-0001-5906-7435
Bentao ShiDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer, a prevalent malignant neoplasm of the urinary tract, exhibits escalating morbidity and mortality rates. Current diagnosis standards rely on invasive and costly cystoscopy and histopathology, underscoring the urgency for non-invasive, high-throughput, and cost-effective novel diagnostic techniques to ensure timely detection and standardized treatment. Recent years have witnessed the rise of exosome research in bladder cancer studies. Exosomes contain abundant bioactive molecules that can help elucidate the intricate mechanisms underlying bladder cancer pathogenesis and metastasis. Exosomes hold potential as biomarkers for early bladder cancer diagnosis while also serving as targeted drug delivery vehicles to enhance treatment efficacy and mitigate adverse effects. Furthermore, exosome analyses offer insights into the complex molecular signaling networks implicated in bladder cancer progression, revealing novel therapeutic targets. This review provides a comprehensive overview of prevalent exosome isolation techniques and highlights the promising clinical utility of exosomes in both diagnostic and therapeutic applications in bladder cancer management.

Indexed as

Biomarkers, TumorExosomesUrinary Bladder NeoplasmsAnimalsDrug Delivery SystemsHumansBiomarkers, Tumorbiomarkersbladder cancerexosomesisolation methodstreatment

Identifiers

PMID38681092
PMCPMC11048230

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.